Annovis Bio (ANVS) News Today $1.98 +0.05 (+2.32%) Closing price 05/20/2026 03:59 PM EasternExtended Trading$2.00 +0.01 (+0.55%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Annovis Bio slips after pricing $15M equity offeringMay 20 at 1:15 PM | seekingalpha.comAnnovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying WarrantsMay 20 at 8:00 AM | globenewswire.comAnnovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying WarrantsMay 19 at 4:06 PM | globenewswire.comAnnovis Provides Corporate Updates and Reports First Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comAnnovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026May 7, 2026 | globenewswire.comAnnovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature PortfolioApril 28, 2026 | globenewswire.comAnnovis Bio, Inc. (NYSE:ANVS) Sees Significant Increase in Short InterestApril 28, 2026 | marketbeat.comTraders Buy Large Volume of Annovis Bio Call Options (NYSE:ANVS)April 23, 2026 | marketbeat.comAnnovis Bio Inc.April 20, 2026 | barrons.comAnnovis Bio (ANVS) price target increased by 13.94% to 15.98April 10, 2026 | msn.comAnnovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA SubmissionApril 10, 2026 | globenewswire.comAnnovis Bio stock tumbles 26% on dilutive equity offeringApril 9, 2026 | in.investing.comAnnovis Bio platziert Aktienangebot über 10 Mio. US-Dollar mit AbschlagApril 9, 2026 | de.investing.comAnnovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying WarrantsApril 9, 2026 | globenewswire.comAnnovis Bio highlights buntanetap development in published articleApril 8, 2026 | msn.comInsider Buying: Annovis Bio (NYSE:ANVS) Director Buys 713,800 Shares of StockApril 4, 2026 | insidertrades.comAnnovis Bio, Inc. Secures Patent for Buntanetap in Prevention and Treatment of Neurological Injuries from Infectious AgentsApril 2, 2026 | quiverquant.comQAnnovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain InfectionsApril 2, 2026 | globenewswire.comAnnovis Publishes Historical Review of Buntanetap in The ScientistMarch 31, 2026 | globenewswire.comAnnovis partners with NeuroRPM to add AI monitoring in PD studyMarch 26, 2026 | msn.comAnnovis reports 2025 results, advances buntanetap trialsMarch 24, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Warby Parker (WRBY) and Annovis Bio (ANVS)March 20, 2026 | theglobeandmail.comAnnovis Unchanged on Hookup with NeuroRPMMarch 19, 2026 | baystreet.caNeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical TrialMarch 19, 2026 | globenewswire.comAnnovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease StudyMarch 19, 2026 | globenewswire.comAnnovis Bio Inc.: Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial ResultsMarch 16, 2026 | finanznachrichten.deAnnovis Bio, Inc. Announces Business Updates and Financial Results for Fiscal Year 2025, Highlighting Pivotal Advances in Buntanetap Development for Neurodegenerative DiseasesMarch 16, 2026 | quiverquant.comQAnnovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial ResultsMarch 16, 2026 | globenewswire.comAnnovis Bio to present buntanetap clinical data at AD/PD 2026 conferenceMarch 10, 2026 | msn.comAnnovis Announces Two Presentations at the AD/PD™ 2026 International ConferenceMarch 3, 2026 | globenewswire.comMalvern-based Annovis continues phase 3 Alzheimer’s trial after safety reviewFebruary 17, 2026 | msn.comAnnovis Bio Inc.: Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's DiseaseFebruary 13, 2026 | finanznachrichten.deAnnovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s DiseaseFebruary 12, 2026 | finance.yahoo.comAnnovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's DiseaseFebruary 12, 2026 | globenewswire.comAnnovis Bio reports open-label extension study for Parkinson’s disease patientsDecember 19, 2025 | msn.comAnnovis Announces Open-Label Extension Study for Parkinson's Disease PatientsDecember 18, 2025 | globenewswire.comAnnovis to Host Corporate Update Webinar on January 28, 2026December 16, 2025 | globenewswire.comInsider Buying: Annovis Bio (NYSE:ANVS) Director Buys 45,000 Shares of StockDecember 9, 2025 | insidertrades.comAnnovis To Present at the 2025 Annual Meeting of the Parkinson Study GroupDecember 3, 2025 | globenewswire.comMichael Hoffman Buys 39,200 Shares of Annovis Bio (NYSE:ANVS) StockNovember 26, 2025 | insidertrades.comAnnovis Bio: Direktor Hoffman kauft Aktien im Wert von 159.000November 25, 2025 | de.investing.comAnnovis Announces Two Presentations at the CTAD 2025 ConferenceNovember 24, 2025 | globenewswire.comAnnovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's PatientsNovember 19, 2025 | benzinga.comAnnovis Bio (NYSE:ANVS) Director Buys $31,650.00 in StockNovember 19, 2025 | insidertrades.comAnnovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying PromiseNovember 19, 2025 | msn.comAnnovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease DementiaNovember 18, 2025 | msn.comFDA-Termin für Parkinson-Medikament lässt Aktie von Annovis Bio steigenNovember 18, 2025 | de.investing.comAnnovis Bio: FDA-Gespräch zu Parkinson-Demenz für Januar 2026 angesetzt – Aktie steigt um über 40 %November 18, 2025 | de.investing.comAnnovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease StudyNovember 18, 2025 | globenewswire.comAnnovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's PatientsNovember 17, 2025 | globenewswire.com Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANVS Media Mentions By Week ANVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANVS News Sentiment▼-0.750.38▲Average Medical News Sentiment ANVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANVS Articles This Week▼62▲ANVS Articles Average Week Get the Latest News and Ratings for ANVS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Annovis Bio and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ALX Oncology News Today LENZ Therapeutics News Today Zentalis Pharmaceuticals News Today Amarin News Today Akebia Therapeutics News Today Nuvectis Pharma News Today Rezolute News Today Prelude Therapeutics News Today Organogenesis News Today Editas Medicine News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANVS) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
